ESC 365 - SGLT2 Inhibitors: diabetes or cardiovascular drugs?

ESC Premium Access

SGLT2 Inhibitors: diabetes or cardiovascular drugs?

Session: Five things cardiologists should know about diabetes

Topic: Cardiovascular Disease in Special Populations

Speaker: Professor L. Leiter (Toronto, CA)

Sponsored by MSD

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Lawrence Leiter

University of Toronto, Toronto (Canada)

19 presentations

0 follower

6 more presentations in this session

Welcome and opening remarks.

Speaker: Professor D. McGuire (Dallas, US)

Diabetes takes a center stage in overall risk for patients with cardiovascular disease .

Speaker: Doctor A. Gitt (Ludwigshafen, DE)

Ertugliflozin – A newly emerging SGLT2 inhibitor for patients with type 2 diabetes.

Speaker: Doctor S. Dagogo-Jack (Memphis, US)

Questions & Answers.

Speaker: Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US) Doctor A. Gitt (Ludwigshafen, DE) Professor L. Leiter (Toronto, CA)

Envisioning the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease: a roundtable discussion.

Speaker: Professor L. Leiter (Toronto, CA) Doctor A. Gitt (Ludwigshafen, DE) Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US)

Access the full session

Five things cardiologists should know about diabetes

Speakers: Professor L. Leiter, Professor D. McGuire, Doctor A. Gitt, Doctor S. Dagogo-Jack, Professor D. McGuire...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources